These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 31426130)

  • 21. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
    Zhao M; Tominaga Y; Ohuchida K; Mizumoto K; Cui L; Kozono S; Fujita H; Maeyama R; Toma H; Tanaka M
    Cancer Sci; 2012 Jan; 103(1):58-66. PubMed ID: 21954965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
    Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
    Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
    Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
    Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway.
    Ma H; Kong L; Liu L; Du Y; Zhu X; Wang J; Zhao W
    Mol Carcinog; 2024 Jul; 63(7):1221-1234. PubMed ID: 38517039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
    Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
    Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
    Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
    J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
    Yao N; Chen Q; Shi W; Tang L; Fu Y
    Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
    Zou J; Su H; Zou C; Liang X; Fei Z
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment.
    Zhang W; Xu Z; Du Y; Liu T; Xiong Z; Hu J; Chen L; Peng X; Zhou F
    Cell Death Dis; 2024 Sep; 15(9):657. PubMed ID: 39242557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
    Kurata N; Fujita H; Ohuchida K; Mizumoto K; Mahawithitwong P; Sakai H; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Aug; 39(2):473-82. PubMed ID: 21617862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of
    Phan T; Nguyen VH; Buettner R; Morales C; Yang L; Wong P; Tsai W; Salazar MD; Gil Z; Diamond DJ; Rabinowitz JD; Rosen S; Melstrom LG
    Int J Biol Sci; 2021; 17(9):2240-2251. PubMed ID: 34239352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Palam LR; Gore J; Craven KE; Wilson JL; Korc M
    Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
    Tian Y; Han W; Fu L; Lv K; Zhou X
    Environ Toxicol; 2023 Aug; 38(8):1835-1845. PubMed ID: 37186415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
    Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
    J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
    Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.